The 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...

Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Individuals are managed by specialist teams, but primary care will maintain a ... of these signals and timely communication ...

The 51-year-old from Northamptonshire, in central England, was diagnosed with incurable cancer in 2015 ... he would have ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

“The MMAI risk classifier is a more precise and accurate prognosticator of metastasis than NCCN risk groups,” Dr Tward’s team wrote. “This approach aims to prevent both overtreatment and ...

Though clinical trials and new developments will increase the effectiveness of treatment, Dr Bouey pointed out that many cost ...

Researchers at the Center for Genomic Regulation (CRG) reveal that metabolic enzymes known for their roles in energy ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the completion of a study ...